Seaport Therapeutics, Inc.
SPTXNasdaq
$20.85
↑ +6.8%Jul 17 close · end-of-day
Price
1Y↑ +5.1%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
No screener snapshot for this ticker.
Company profile
We are a clinical-stage therapeutics company focused on inventing and developing new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. Through our differentiated approach, we identify clinically validated mechanisms with established efficacy and safety profiles which had historically been limited by high first-pass metabolism, low bioavailability, and/or side effects. Our principal executive offices are located in Boston, Massachusetts.
- CEO
- Daphne Zohar
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 58
- Headquarters
- Massachusetts
- Website
- seaporttx.com
Management & directors
- Chen Michael CunyuanChief Scientific Officer
- Gladstein LanaGeneral Counsel
- Loebel AntonyChief Medical Officer
- White LaurenChief Financial Officer
Roles derived from SEC Form 4 filings.
Earnings
SPTX Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$10.34↑ +83.0%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
No annual data.
| Line item | Q1 '25 | Q1 '26 |
|---|---|---|
| Revenue | — | — |
| Gross profit | — | — |
| Operating income | -$16.2M | -$27.5M |
| Net income | -$13.1M | -$25.4M |
| Diluted EPS | -$5.65 | -$10.34 |
| Operating cash flow | -$20.2M | -$20.2M |
| Free cash flow | -$20.3M | -$20.2M |
| Gross margin | — | — |
| Operating margin | — | — |
| Net margin | — | — |
Company news
Jun 8, 2026
- 42d agoSeaport Therapeutics Reports First Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progressfinance.yahoo.com
- 42d agoSeaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgo™ in Healthy Volunteersfinance.yahoo.com
Jun 1, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-06-22 | HOMBACH ROBERT J. | Buy | 13,000 | $18.14 | $235,768.00 | filing |
| 2026-05-04 | ARCH Venture Partners XII, LLC | Buy | 1,100,000 | $18.00 | $19.8M | filing |
| 2026-05-04 | PureTech Health plc | C | 2,681,265 | — | — | filing |
| 2026-05-04 | PureTech Health plc | C | 965,255 | — | — | filing |
| 2026-05-04 | HEALY JAMES | C | 1,927,159 | — | — | filing |
| 2026-05-04 | HEALY JAMES | C | 804,379 | — | — | filing |
| 2026-05-04 | White Lauren· Chief Financial Officer | C | 6,702 | — | — | filing |
| 2026-05-04 | Gladstein Lana· General Counsel | C | 33,515 | — | — | filing |
| 2026-05-04 | Chen Michael Cunyuan· Chief Scientific Officer | C | 3,351 | — | — | filing |
| 2026-05-04 | Torres Denice | C | 13,406 | — | — | filing |
| 2026-05-04 | PAUL STEVEN M | C | 67,031 | — | — | filing |
| 2026-05-04 | ARCH Venture Partners XII, LLC | C | 2,513,686 | — | — | filing |
| 2026-05-04 | ARCH Venture Partners XII, LLC | C | 2,681,265 | — | — | filing |
| 2026-05-04 | Loebel Antony· Chief Medical Officer | C | 20,109 | — | — | filing |
| 2026-05-04 | PureTech Health plc | C | 12,736,014 | — | — | filing |
Latest 15 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.